Illumina, Inc.   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: San Diego CA United States (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2020
NCT04535193
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Illumina, Inc. | Illumina Radiopharmaceuticals, LLC | Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

Active Ingredients

Drugs in Phase 4 Trials (14)

Key: Illumina, Inc. (0) Acquired (14)

10-valent Pneumococcal Conjugate Vaccine (Pneumosil) (1 trial)

amodiaquine (camoquin) (3 trials)

artesunate (3 trials)

ciprofloxacin (cipro) (2 trials)

coartem (4 trials)

dihydroartemisinin (1 trial)

killed oral cholera vaccine (1 trial)

levobupivacaine (chirocaine) (1 trial)

lumefantrine (Coartem) (4 trials)

morphine (1 trial)

piperaquine (1 trial)

quadrivalent groups a, c, y, and w-135 meningococcal vaccine (Menomune-A/C/Y/W-135) (1 trial)

quinine (qualaquin) (1 trial)

yellow fever vaccine 17d strain (2 trials)

Drugs in Phase 3 Trials (24)

Key: Illumina, Inc. (1) Acquired (23)

18f-mfbg (2 trials)

ad26.zebov (Zabdeno) (1 trial)

azithromycin (zithromax) (1 trial)

bedaquiline (sirturo) (2 trials)

brv-pv (Rotasil) (1 trial)

clofazimine (lamprene) (2 trials)

delamanid (2 trials)

efavirenz (sustiva) (1 trial)

eflornithine (ornidyl) (3 trials)

ethambutol (myambutol) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

isoniazid (nydrazid) (1 trial)

levofloxacin (levaquin) (1 trial)

linezolid (zyvox) (2 trials)

lopinavir (Kaletra) (1 trial)

melarsoprol (1 trial)

moxifloxacin (avelox) (1 trial)

mva-bn-filo (Mvabea) (1 trial)

nevirapine (viramune) (1 trial)

nifurtimox (Lampit) (3 trials)

pyrazinamide (Aldinamide) (2 trials)

rifampin (1 trial)

ritonavir (Norvir) (1 trial)

rvsvdelta-zebov-gp (1 trial)

Drugs in Phase 2 Trials (4)

Key: Illumina, Inc. (0) Acquired (4)

cad3-zebov (1 trial)

chadox1 (1 trial)

nitric oxide (inomax) (1 trial)

rvsv-sudv (1 trial)

Drugs in Other Trials (4)

Key: Illumina, Inc. (0) Acquired (4)

chlorhexidine (hibitane) (1 trial)

fav-africa (1 trial)

procaine benzylpenicillin (novocaine) (1 trial)

tetanus toxoid (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiovascular Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 32
  • # of Trial APIs: 46